RxSpan MD Review: $179 Sermorelin Tablets, No Injection

The short version

RxSpan MD sells sermorelin as an oral dissolving tablet at $179 a month, month to month, dropping to $166 a month if you prepay three months ($499), $150 on six ($899) and $142 on twelve ($1,699). That is a properly built ladder: a real monthly rung at the top, a genuine discount for term, and no intro teaser propping up the headline.

The problem is what the ladder is attached to. The tablet is the only sermorelin RxSpan will actually sell you. Its catalog still prices a sermorelin injection at $199 a month, $549 for three, $997 for six and $1,797 for twelve, but the injection appears on none of its four treatment pages and in none of the four tabs of its product index. The homepage even lists "Sermorelin Injection" as an example of what its longevity program offers. Click through and the only sermorelin on the shelf is the tablet.

That matters more here than it would anywhere else, because the two formats are not interchangeable. Every human study showing GHRH(1-29) raises growth hormone used a needle⁵. Nothing comparable exists for a tablet.

Everything else here is better than average. It names four dispensing pharmacies with phone numbers, two prescribing physicians with NPIs that verify, a real corporate address, and answers the state question directly. Of the 33 providers we track, only eight name a dispensing pharmacy at all.

The ladder, and the rung to actually buy

Open the longevity page, pick Sermorelin ODT, and the plan selector prices four rungs: Monthly at $179 a month, a three-month plan at $166, six months at $150 and twelve months at $142, tagged "Max Saving". A promo code, STARTNOW, was taking 10% off across the site on the day we looked, which put a single month at $161.

Two things about that selector are worth knowing before you touch it.

The default is not the monthly rung. Land on the page and the three-month plan is already selected. Press the button marked Next without changing anything and you are carried into the intake with the $499 three-month tablet loaded, not the $179 one. Choosing Monthly first genuinely works — it swaps the item behind the button — but it is a deliberate act, not the path of least resistance.

The discount for prepaying is thinner than it looks. Three months at $166 saves you about $13 a month against paying monthly, so a $499 commitment buys $38 of savings across the quarter. Even the twelve-month rung only takes $37 a month off the monthly rate. Weigh that against what you are committing to: a compounded drug that is not FDA-approved⁸, in a format with no published human absorption data.

So: buy the $179 month. It is one of the few genuine month-to-month sermorelin rates on our ranking, the ladder will still be there in eight weeks, and the savings you give up by not prepaying are smaller than the cost of one wrong three-month bet.

The injection you can read about and cannot buy

RxSpan's storefront serves its whole price list openly, which is how the injection figures above can be quoted at all. Sermorelin Injection is in that list at $199 a month, flagged visible, alongside three prepay rungs. It is simply not on any page.

We checked all four treatment categories and all four tabs of the product index on 29 August 2026. The longevity page lists ten items — NAD+ in three formats, the sermorelin tablet, MIC B12, methylene blue, glutathione, GHK-Cu, Lipo C and PT-141. No injection. The homepage advertises one.

That leaves a buyer in an odd position: the format with the evidence behind it is priced, published and unreachable, while the format without it sits on the shelf at $20 a month less. Nothing on the site tells you the injection is even available to ask for.

Who fills it, and who signs for it

This is where RxSpan is genuinely good, and where the earlier record of this company went wrong. Its homepage carries an FAQ whose panels are shut by default and load after the page does — read the page as text with the panels closed and it appears to name nobody. Open them and it names, verbatim:

• •Belmar Pharmacy (800-525-9473), Strive Pharmacy (855-405-5993), Epiq Scripts (833-654-3553) and Casa Pharma Rx (877-937-6868), each with its website.
• •Lion MD, described as a nationwide team, "led by Dr. Ana Lisa Carr, MD (NPI: 1689841744) and Dr. Kelly Tenbrink, MD (NPI: 1346482684)."
• •On states: "all 50 U.S. states", with availability of specific services varying by provider licensure.

We looked both NPIs up in the federal registry on 29 August 2026 and both are active and real². Dr Carr is listed in family medicine, with California as her primary license state; Dr Tenbrink is listed in emergency medicine, with Tennessee as hers. Neither is listed in endocrinology, and neither is the founder.

Three qualifiers, and they are the reason this is praise rather than a recommendation on its own.

The bench is shared. Those same four pharmacies and those same two physicians, in near-identical wording, are published by Care Bare Rx and Synergy Rx, and Pallas Health names the same clinical group. All of them run on the same white-label platform. So the disclosure is real, and it describes the supply chain your prescription passes through — not something RxSpan arranged and its neighbors did not.

One of the four carries a letter, and it is closed. The FDA issued a warning letter to Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy in March 2023, and that letter was closed out on 30 October 2023³. Closed out means the agency has recorded that the matters raised were addressed. We are not restating what it said — that is the agency's account to give, and it sits on the agency's own index. We say it exists, who it was addressed to, when, and that it is closed, because you are entitled to hear it from us rather than find it afterwards. RxSpan MD itself has nothing on record, and neither do Strive, Epiq Scripts or Casa Pharma Rx (how we check).

No compounding tier is claimed. The strings 503A and 503B appear nowhere on the ten pages we read. RxSpan names its pharmacies; it makes no representation about which class they operate under, and you should not read four names as a quality claim. That distinction is worth understanding before you buy any compounded peptide⁸.

The founder is named and detailed: Dr John Diaz, a board-certified plastic surgeon with more than twenty years in practice, Cornell undergraduate, Albert Einstein College of Medicine, MD with Distinction in Research. It is an unusually specific biography — and a plastic surgery biography attached to a growth-hormone product, with no NPI or state license number published for him anywhere on the site.

What it does not publish

The company operates as RxSpan MD LLC, 465 N Roxbury Drive, Penthouse Suite, Beverly Hills, CA 90210 — a real named entity at a real address, which more of this market should manage. Its Terms of Service, Privacy Policy, Telehealth Medical Consent and Notice of Privacy Practices all carry the same date, 3 June 2026.

They also carry very little. Across those four documents and the six other pages we read:

• •The word "refund" does not appear once. Nor does "return". The checkout says a provider reviews your information after you pay and that "prescription is not guaranteed" — and the site never says what happens to your money if the answer is no. Other brands on the same platform publish an $80 charge when nothing is prescribed; RxSpan publishes nothing at all. Ask before you pay.
• •No governing law, no arbitration clause, no cancellation terms. The plan overview promises you can "cancel or change plans anytime", and nothing in the Terms defines what that means or by when.
• •No dose and no strength, for either format. Every sermorelin listing carries the same generic footnote and no milligrams, so you cannot compare what $179 buys against a provider that publishes a per-milligram figure.
• •The letters FDA appear nowhere. The site never tells a reader that compounded sermorelin is not an FDA-approved product. It is not.
• •A phone number. The only contact published is an email address.

There is one more asymmetry worth naming, because it is visible on the same site within two clicks. RxSpan's weight-loss cards are models of disclosure: each shows a "Regular Monthly Price", an "as low as" rate, the exact upfront sum ("billed as one upfront payment of $2,094"), the words "Auto-renews", a note that the promo is applied and a warning that the final price is confirmed at checkout. The sermorelin card, on the same site, on the same day, shows "$179" and the parenthetical "(For the first month)" — while the plan selector two inches below prices the same figure as "Monthly $179/mo" and the site publishes no month-two number anywhere. The company knows how to write a price card. It has not written one for this product.

One last thing to ask about rather than assume: the plans are described as "pre-paid monthly, quarterly, semi-annually, or annually", while the storefront's own settings bill on a four-week cycle. Four weeks is thirteen charges a year, not twelve. We could not confirm that at checkout, so treat it as a question for support, not a fact.

Does a sermorelin tablet make sense at all?

Sermorelin is a synthetic copy of the first 29 amino acids of growth-hormone-releasing hormone. It supplies no growth hormone; it prompts your own pituitary to release more of yours⁴, which is why it is dosed at night and why the best-supported effects are on sleep and the GH/IGF-1 axis rather than on the mirror. Nightly injected GHRH(1-29) raised GH and IGF-1 in healthy older men in a controlled study⁵, and the broader literature on augmenting growth hormone in healthy adults finds small body-composition changes, no functional gain and a real side-effect rate⁷.

Every one of those findings used a needle. Peptides swallowed or dissolved in the mouth face a wall of enzymes and a membrane they cross badly: even the oral peptide drugs that cleared FDA review, with absorption enhancers engineered into the tablet, land around 1% bioavailability⁶. No published human trial shows that oral or sublingual sermorelin raises anyone's IGF-1. We walk through the pharmacology in full in oral and sublingual sermorelin, and grade the underlying claims in our evidence review.

So RxSpan sells the cheaper format, and the cheaper format is the one with no absorption evidence behind it — as the only option it offers.

Verdict

RxSpan MD does the hard part of disclosure and then stops short on the easy part. It names four pharmacies with phone numbers, two physicians with NPIs that verify, a real corporation at a real address and all fifty states, which puts it among the better-documented services we track. Read those names as facts about the platform it runs on rather than about this brand, and note that one of the four pharmacies carries a March 2023 warning letter that was closed out in October 2023.

Then it publishes no refund policy, no dose, no cancellation terms and no phone number, hides its best price behind a card that calls it a first-month rate, defaults you to a three-month prepay, and sells only the sermorelin format that has never been shown to be absorbed.

If you want it anyway: choose the Monthly rung, not the default, and email before you pay to ask what happens if you are declined and whether the injection can be prescribed. If the answer to the second question is yes, take it. If the format matters less to you than the price, our price-sorted list shows who else sells a real month-to-month rate and what they charge for it.